Willis Towers Watson plc — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report; it does not provide a separate fourth-quarter income statement summary. Financial figures are in U.S. dollars unless noted.
Business context
WTW is a global advisory, broking and solutions company focused on people, risk and capital, with approximately 48,000 colleagues serving more than 140 countries and markets. Its two reportable segments are Health, Wealth & Career (HWC) and Risk & Broking (R&B). WTW earns most revenue through brokerage commissions and consulting and administration fees; it does not underwrite insurance risk. No customer represented more than 10% of revenue.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change / context |
|---|---|---|---|
| Revenue | $9.483 billion | $8.866 billion | Up 7% reported; organic growth 8% |
| Income from operations | $1.365 billion | $1.178 billion | Up $187 million; GAAP operating margin 14.4%, versus 13.3% |
| Adjusted operating income and margin | $2.082 billion; 22.0% | $1.851 billion; 20.9% | Non-GAAP; excludes specified items including amortization and transformation costs |
| Net income attributable to WTW | $1.055 billion | $1.009 billion | Up $46 million |
| Diluted EPS from continuing operations | $9.95 | $9.34 | Up from prior year |
| Adjusted diluted EPS | $14.49 | $13.41 | Non-GAAP; benefited partly from a lower diluted share count |
| Cash from operating activities | $1.345 billion | $812 million | Higher operating cash generation |
| Free cash flow | $1.192 billion | $674 million | FCF margin 12.6%, versus 7.6%; non-GAAP liquidity measure |
| Cash and cash equivalents | $1.424 billion | $1.262 billion | Separately, $2.368 billion of fiduciary funds was held in restricted capacity |
| Total debt | $5.217 billion | $4.721 billion | Interest expense was $235 million, versus $208 million |
The $1.5 billion revolving credit facility was undrawn at year-end. WTW reported $650 million of 3.600% senior notes due in 2024 and said it was in compliance with its financial covenants. Management said available liquidity was sufficient for expected needs over the next 12 months. Fiduciary assets are matched by fiduciary liabilities and are not available for corporate purposes.
Segment revenue was $5.582 billion for HWC, up 6%, and $3.735 billion for R&B, up 8%. Segment operating income rose to $1.565 billion from $1.382 billion for HWC and to $813 million from $734 million for R&B. Segment revenue is presented on a basis that differs from consolidated GAAP revenue.
Material changes versus FY2022
- Revenue and both segments grew; management cited higher activity in Medicare placements and outsourcing, Retirement and Investments, benefits consulting, compensation services, brokerage new business and retention, and insurance software and project work.
- Operating income improved with higher revenue, lower restructuring costs and no repeat of the prior-year $81 million Russian-related impairment. Higher salaries and benefits and substantially higher transaction and transformation costs partly offset the improvement.
- Transaction and transformation expense increased to $386 million from $181 million. Other income, net declined to $149 million from $288 million, mainly due to lower pension income, partly offset by higher disposal gains.
- Operating cash flow increased from $812 million to $1.345 billion. Management attributed the rise partly to improved operating margins and the non-recurrence of prior-year cash headwinds, including certain compensation, tax and foreign-exchange items.
- WTW repurchased $1.0 billion of shares in 2023, compared with $3.5 billion in 2022; year-end repurchase authorization remaining was approximately $1.3 billion. Cash dividends paid were $352 million.
Outlook, commentary, risks and unusual items
- Transformation program: WTW expects annual cost savings exceeding $425 million by the end of 2024. Revised expected cumulative costs are approximately $995 million, plus approximately $130 million of capital expenditures, for total investment of $1.125 billion. The company reported $337 million of cumulative identified annualized run-rate savings through 2023. Achievement, timing and costs remain uncertain.
- Near-term spending: Capital expenditures for fixed assets and internal-use software are expected to be $175–$200 million in 2024. Management expects operating cash to fund these needs.
- Market conditions: Management described the insurance market as stabilizing. Brokerage commissions remain exposed to insurance premium movements, market softness, competition and client decisions to retain risk or self-insure. Management cautioned that economic and geopolitical uncertainty, inflation and interest-rate changes may affect costs, demand and liquidity.
- Willis Re sale: The sale to Gallagher was completed, with remaining co-broking arrangements ended and related assets and liabilities transferred in 2023; $922 million of cash and fiduciary funds transferred in investing activities. A potential earnout of up to $750 million, subject to adjustments and conditions, may be payable in 2025; it was not recorded as a receivable because receipt was not yet certain. Transitional services were extended through May 31, 2024, with possible further extension.
- Pension and goodwill sensitivity: Pension assumptions and market movements can affect obligations, expense and cash contributions. No goodwill impairment was recorded in 2023, but the Benefits Delivery & Administration reporting unit had only a 6.4% estimated fair-value cushion and $2.3 billion of goodwill, making it sensitive to valuation assumptions and business performance.
- Other key risks: The filing highlights professional-liability claims and contingencies, regulatory and legal changes affecting Medicare and health benefits, cyber and data-security threats, foreign-exchange exposure, competition, and macroeconomic and geopolitical disruption. The filing says existing claims are not expected to have a material adverse effect overall, but an adverse outcome could materially affect an individual period.
- Audit and controls: Deloitte issued unqualified opinions on the financial statements and internal control over financial reporting. The audit identified critical audit matters involving the errors-and-omissions reserve and BDA goodwill valuation; these are not separate audit opinions.
Important facts for investors to verify
- Track delivery of the $425 million-plus transformation savings target against remaining program costs, capital spending and any disruption to operations.
- Review the BDA goodwill cushion and underlying revenue, margin and discount-rate assumptions for impairment sensitivity.
- Assess the 2024 $650 million note maturity, refinancing or repayment, debt costs and liquidity available after planned investment, dividends and buybacks.
- Monitor the Gallagher earnout conditions and any remaining transition-service obligations, costs or liabilities.
- Check future Medicare marketing and broker-compensation rules, pension funding requirements, and developments in significant E&O or regulatory matters.